🔗 Share this article

As America undertakes unprecedented adjustments to its immunization guidelines, one figure has emerged somewhat surprisingly: Høeg, a Danish American physician and epidemiologist who initially gained attention by questioning COVID-19 shots in the pandemic and has zeroed in on possible fatalities following COVID-19 immunization in her recent position at the US Food and Drug Administration (FDA).

Scheduled Shifts to Pediatric Vaccine Program

Public health authorities planned to unveil sweeping changes to the childhood vaccination calendar earlier this month, bringing the US with the Danish vaccine program, according to reports – a major change that would put the US out of alignment with a large portion of the international standard with little proof for public health gain. The announcement has been pushed back until the new year.

Rather than the director of the vaccine center, Dr. Høeg is set to present at the event. She was recently named interim head of the FDA’s CDER, the fifth appointee to head the office this calendar year.

A Shift at the Agency

This interim role might represent a strengthened alliance between the drug and vaccine centers as Dr. Høeg and Prasad strengthen their influence at the agency – and it suggests a renewed priority upon rolling back already-approved immunizations at the FDA.

Høeg has frequently advocated for halting some childhood shot schedules in the US so as to align more similar to Denmark's approach, a nation with universal health coverage and a number of inhabitants approximately the population of the state of Wisconsin.

So far statements, she has kept her attention on vaccines – typically the responsibility of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Concerns Over Qualifications

Dr. Høeg has no apparent experience in medication creation, oversight or management, which has been typical for previous leaders of the biologics center. She has been employed at the FDA as a top consultant to the commissioner and the vaccine center since earlier this year.

“She appears not to have the requisite experience” for leading the pharmaceutical oversight division, stated a neurologist and psychiatrist. “She’s never run a clinical trial. She has no expertise in running a large organization. She has no expertise in pharmaceutical oversight.”

Former directors of CBER would “understand legal statutes and the research of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Objectively, she lacks the kind of background that former directors who led the center have had.”

CDER has an immense portfolio at the FDA, she pointed out.

“Many people just pays attention on the novel medication approvals, but the generic drug division clears thousands of generic medications. There’s a biosimilars program, over-the-counter program and so forth, and every single one have to be looked after,” she noted. “The responsibility you overlook, that is precisely what that I always told people is going to come back to haunt you.”

There is also, a substantial administrative aspect to the role, which manages in excess of 5,000 staff members. “It’s a enormous management job, if you perform it correctly,” she added.

Official Statement and Controversial Programs

In response to inquiries about Høeg’s fitness for the role and whether this selection signifies greater collaboration among regulatory chiefs on vaccines, a representative responded that the “questions stem from flawed presumptions”.

“This background matches the responsibilities of her role,” the representative explained, citing the months Høeg spent advising the agency head on “drug safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Dr. Høeg takes over the agency head's recently launched priority voucher program, a controversial expedited medication authorization process that allegedly worried her former heads. “By what process are these therapies being selected for this expedited pathway? Who takes the calls?” Dr. Howard questioned. “There is a lot of lack of transparency occurring at the regulatory body right now.”

In general, he stated, “the agency seems to be moving towards more relaxed oversight of pharmaceuticals, except for vaccines.”

Documented History on Vaccines

Regarding immunizations, Dr. Høeg has a more established, if concerning, history, critics said. She authored a analysis using non-validated public submissions to determine the rate of heart inflammation after Covid immunization. She advised the state of Florida chief medical officer Joseph Ladapo, who allegedly have modified findings to indicate Covid vaccinations are pose a greater threat than they are.

Included in her “policy goals” for the new government included revising guidelines for new vaccines and ending “optional” vaccines, she said post-election on a podcast. At the FDA, Høeg has allegedly floated the idea of excluding young men from obtaining Covid vaccines.

“She is an all-around dogmatist who begins with her conclusions and works backwards to retrofit the data in a extremely disingenuous, dishonest manner,” Howard stated.

Gaining Influence and a “Push for Payback”

Dr. Høeg aligned with fellow contrarians, {like|